Our data suggest a potentially useful role for troglitazone as a therapeutic agent to reduce and/or reverse EMT of alveolar epithelium associated with IPF, in which colocalization of β-catenin and Smad3 have been identified in hyperplastic AT2 cells [41]. Here, SMAD3 is linked to idiopathic pulmonary fibrosis.